RNAi

Type: Keyphrase
Name: RNAi
First reported 10 hours ago - Updated 10 hours ago - 1 reports

Corn trait use broadens with new introductions

Seed companies continue to research new products to improve corn yields.John Long, Mycogen Seeds customer agronomist, says Dow AgroSciences is preparing to launch Enlist trait corn in 2015 based on government approvals.Eric Boersma, Syngenta's head of ... [Published Midwest Producer - 10 hours ago]
First reported 15 hours ago - Updated 15 hours ago - 1 reports

EIF4F affects dexamethasone response in myeloma [Genetics]

Francis Robert a , William Roman b , Alexandre Bramoullé c , Christof Fellmann d , Anne Roulston c , Chaim Shustik b , John A. Porco, Jr. e , Gordon C. Shore a , c , Michael Sebag b , 1 , and Jerry Pelletier a , c , f , 1 Departments of a Biochemistry, ... [Published PNAS - 15 hours ago]
First reported 19 hours ago - Updated 19 hours ago - 1 reports

The Second Coming of RNAi

THE ART OF SILENCING: Small interfering RNA molecules are incorporated into an RNA-induced silencing complex where they bind and degrade target messenger RNAs (yellow with red rings). Taking advantage of this natural RNA interference (RNAi) pathway, researchers ... [Published The Scientist - 19 hours ago]
First reported 23 hours ago - Updated 22 hours ago - 1 reports

Silence Therapeutics : Board change

Silence Therapeutics plcBoard changeSilence Therapeutics plc, AIM: SLN, announces that due to family commitments, Chief Operating Officer Annie Cheng has resigned from the Board with effect from today, ahead of moving back to New York early next year ... [Published Investegate - 23 hours ago]
First reported Aug 28 2014 - Updated Aug 29 2014 - 2 reports

Study Shows How Premalignant Cells can Sense Oncogenesis and Halt Growth

New research shows how premalignant cells can respond to an activated RAS gene by entering a quiescent state, called senescence and halt cancer growth.CSHL Professor Nicholas Tonks and Benoit Boivin, now a University of Montreal Assistant Professor, co-led ... [Published MedIndia - Aug 29 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

RNAi - technologies, markets and companies

RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material is processed into short 21-23 nucleotide RNAs termed siRNAs that are used in a sequence-specific manner to recognize and destroy ... [Published Global Information Inc - Aug 29 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Antiviral Therapeutics - technologies, markets and companies

This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. Various antiviral approaches are described including pharmaceuticals and molecular biological ... [Published Global Information Inc - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Plants can turn off virus DNA

The research comes from Wageningen UR in the Netherlands.From HortiDaily:A team of virologists and plant geneticists at Wageningen UR (University and Research centre) has demonstrated that when tomato plants contain Ty-1 resistance to the important Tomato ... [Published Produce Grower - Aug 28 2014]
Entities: Virus, DNA, RNAi
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Corn trait use broadens with few new introductions

Seed companies continue to research new products to improve corn yields.John Long, Mycogen Seeds customer agronomist, says Dow AgroSciences is preparing to launch Enlist trait corn in 2015 based on government approvals.Eric Boersma, Syngenta’s head of ... [Published Iowa Farmer Today - Aug 28 2014]
Entities: Corn, John Long, Joe Walsh
First reported Aug 28 2014 - Updated Aug 28 2014 - 2 reports

USPTO issues notice of allowance for claims in Alnylam's Tuschl patent application

Alnylam Pharmaceuticals (ALNY), a leading RNAi therapeutics company, has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Tuschl et al. patent application 12/591,829. ... [Published PBR - News - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Tekmira Pharmaceuticals Corp. Is More Than Just A Short-Term Trade

By KarinCA :Tekmira Pharmaceuticals Corp (NASDAQ: TKMR ) is located in Vancouver Canada and is a world leader in RNA interference , RNAi . Description of RNAi from the TKMR website:Related Biotechnology, Pharmaceutical and Healthcare News" RNAi has the ... [Published BioPortfolio - Aug 27 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Tekmira Pharmaceuticals Corp. Is More Than Just A Short-Term Trade

Summary Ebola has thrust a virtually unknown company into the spotlight. Unknown to average retail investors, but, not unknown in it’s industry. Tekmira has some interesting technology and partners. The pipeline may turn this into a longer term hold ... [Published Seeking Alpha - Aug 27 2014]

Quotes

"A lot of work is being done with high- and low-plant populations" said Boersma
"Annie has made a valuable contribution to our strategic direction. She will work closely with the Company over the coming months, with a view to a consulting role when she is back in the US." Silence Therapeutics plc
...” It was part of a Bush administration initiative called Project Bioshield, meant to "help America purchase, develop and deploy cutting-edge defenses against catastrophic attack" following the events of Sept. 11. Since then, the funding has only increased
According to the new research report  " Oligonucleotide Synthesis Market by Product & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical & Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNA i ) - Global Forecast to 2019 " published by MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected to reach $1,712.1 Million by 2019 from $1,070...

More Content

All (471) | News (293) | Reports (0) | Blogs (156) | Audio/Video (0) | Fact Sheets (3) | Press Releases (17)
sort by: Date | Relevance
Leading Health Care Stock for Small-Cap Stars i... [Published Equities.com - 10 hours ago]
Corn trait use broadens with new introductions [Published Midwest Producer - 10 hours ago]
EIF4F affects dexamethasone response in myeloma... [Published PNAS - 15 hours ago]
Nuclear envelope protein MAN1 regulates clock t... [Published Elifesciences - 17 hours ago]
5 Stocks Poised for Big Breakouts [Published The Street Latest - 18 hours ago]
Dicerna to Present at the Baird 2014 Health Car... [Published InvestorPoint.com - 18 hours ago]
The Second Coming of RNAi [Published The Scientist - 19 hours ago]
Silence Therapeutics : Board change [Published Investegate - 23 hours ago]
Genome-wide siRNA screen reveals coupling betwe... [Published EMBO Journal - Sep 01 2014]
TLR sorting by Rab11 endosomes maintains intest... [Published EMBO Journal - Sep 01 2014]
Ebola, Experimental Drugs and Informed Consent:... [Published Forbes.com - Sep 01 2014]
Ebola Outbreak: Vaccines And Experimental Treat... [Published International Business Times - Aug 30 2014]
Oligonucleotide Synthesis Market Worth $1,712.1... [Published Minyanville - Aug 29 2014]
Study Shows How Premalignant Cells can Sense On... [Published MedIndia - Aug 29 2014]
Drug Delivery in Central Nervous System Disease... [Published Global Information Inc - Aug 29 2014]
Cardiovascular Drug Delivery - technologies,mar... [Published Global Information Inc - Aug 29 2014]
Antiviral Therapeutics - technologies, markets ... [Published Global Information Inc - Aug 29 2014]
RNAi - technologies, markets and companies [Published Global Information Inc - Aug 29 2014]
Plants can turn off virus DNA [Published Produce Grower - Aug 28 2014]
Tekmira Pharmaceuticals (TKMR) Stock Up on Rumo... [Published InvestorGuide.com - Aug 28 2014]
Research shows how premalignant cells can sense... [Published Medical Xpress - Aug 28 2014]
Corn trait use broadens with few new introductions [Published Iowa Farmer Today - Aug 28 2014]
Drug Delivery in Cancer 2014: Technologies, Mar... [Published Pharmacy Choice - Aug 28 2014]
USPTO issues notice of allowance for claims in ... [Published PBR - News - Aug 28 2014]
Alnylam receives notice of allowance for RNAi t... [Published Individual.com - Aug 28 2014]
Tekmira Pharmaceuticals Corp. Is More Than Just... [Published BioPortfolio - Aug 27 2014]
Tekmira Pharmaceuticals Corp. Is More Than Just... [Published Seeking Alpha - Aug 27 2014]
Alnylam Receives Notice of Allowance from Unite... [Published Business Wire Health News - Aug 27 2014]
Leading Health Care Stock for Small-Cap Stars i... [Published Equities.com - Aug 26 2014]
Key Role for Store-Operated Ca2+ Channels in Ac... [Published Plosone.org - Aug 26 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
USPTO issues notice of allowance for claims in ... [Published PBR - News - Aug 28 2014]
Alnylam Pharmaceuticals (ALNY), a leading RNAi therapeutics company, has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Tuschl et al. patent application 12/591,829. ...
Alnylam Receives Notice of Allowance from Unite... [Published Business Wire Health News - Aug 27 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Tuschl et ...
Alnylam Receives Notice of Allowance from Unite... [Published Business Wire Health News - Aug 20 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Tuschl ...
Alnylam Pharmaceuticals Reports Second Quarter ... [Published Business Wire Health News - Aug 07 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2014, and company highlights. “During the second quarter and ...
Delivering on Biotech’s Promise to treat Anthra... [Published I Am Biotech - Aug 07 2014]
Thanks to federal biodefense programs that partner with industry to develop and stockpile medical countermeasures, each year America is better equipped to respond to potential biological, chemical, nuclear and radiological threats, BIO president and ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Tekmira's Lipid Nanoparticle (LNP) Technology T... [Published GlobeNewswire: Acquisitions News - Aug 20 2014]
Tekmira Provides Corporate Update and Announces... [Published GlobeNewswire: Acquisitions News - Aug 13 2014]
Tekmira Conference Call and Webcast Advisory: C... [Published GlobeNewswire: Acquisitions News - Aug 08 2014]
FDA Modifies Tekmira's TKM-Ebola Clinical Hold ... [Published GlobeNewswire: Acquisitions News - Aug 07 2014]
Tekmira Provides Update on TKM-Ebola Phase I Cl... [Published GlobeNewswire: Acquisitions News - Jul 21 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.